Abstract
We evaluated the effects of chemotherapy given postoperatively with and without immunodulators on the survival of patients who had undergone resection for gastric cancer. We conducted a retrospective survey of data on 963 Japanese patients treated at our department of surgery between 1965 and 1987. Data related to the duration of postoperative survival were calculated for those who received chemotherapy, i. e. an individualized combination of various agents given or without the immunomodulators PSK, a protein extract of the fungusCoriolus versicolor, and/or OK-432, a preparation of an attenuated strain ofStreptococcus (immunochemotherapy). Postoperative immunochemotherapy was more often prescribed for patients with advanced disease. The survival of patients who received immunochemotherapy was shorter than that of patients who received only chemotherapy. In a subgroup of patients adjusted for disease stage, the survival of those on chemotherapy versus immunochemotherapy did not differ significantly at any stage. For optimal results, a protocol for postoperative immunochemotherapy needs to be designed and investigated prospectively and according to the stage of gastric cancer. The stage III gastric cancers seem amenable to a favorable response.
Similar content being viewed by others
References
Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Abe R, Watanabe D, Matsuoka H, Ueo H, Akiyoshi T (1992) A trial of adjuvant chemoimmunotherapy with mitomycin C and OK-432 for stage III gastric carcinoma. J Surg Oncol 50: 187
Dixon WJ (ed) (1988) BMDP statistical software. University of California Press, Berkeley, p 229
Douglass HO (1985) Gastric cancer: overview of current therapies. Semin Oncol 12 [Suppl 4]: 57
Estape J, Grau JJ, Leobendas F, Curto J, Daniels M, Vinolas N, Pera C (1991) Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 213: 219
Fielding JWL, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa A, Brookes VS, Craven JL, Mason MC, Timothy A, Waterhouse JAH (1983) An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. World J Surg 7: 390
Gunduz N, Fisher B, Saffer EA (1979) Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39: 3861
Ishii Y, Yamaoka H, Toh K, Kikuchi K (1976) Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Jpn J Cancer Res 67: 115
Japanese Research Society for Gastric Cancer (1981) The General Rules for the Gastric Cancer Study in Surgery and Pathology. I. Clinical classification. Jpn J Surg 11: 127
Japanese Research Society for Gastric Cancer (1981) The General Rules for the Gastric Cancer Study in Surgery and Pathology. II. Histological classification of gastric cancer. Jpn J Surg 11: 140
Kai S, Tanaka J, Nomoto K, Torisu M (1979) Studies on the immunopotentiating effect of a streptococcal preparation, OK-432. I. Enhancement of T-cell-mediated immune responses of mice. Clin Exp Immunol 37: 98
Kano T, Kumashiro R, Tamada R, Kodama Y, Inokuchi K (1981) Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Surg 11: 291
Kikuchi Y, Kizawa I, Oomori K, Iwano I, Kita T, Kato K (1988) Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. Jpn J Cancer Res 79: 125
Krook JE, O'Connell MJ, Wieand HS, Beart RW Jr, Leigh JE, Kugler JW, Foley JF, Pfeifle DM, Twito DI (1991) A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 67: 2454
Kuroda Y, Miura S, Asada Y, Iida A, Mitsui T, Jung Gi K, Katoh Y, Fujisawa K, Minagawa M, Fujisawa M (1989) Evaluation of long-term administration of OK-432 for gastric cancer patients who underwent curative resection — historical control study (in Japanese, with English abstract). Biotherapy 3: 723
Ono T, Kurata S, Wakabayashi K, Sugawara Y, Saito M, Ogawa H (1973) Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro. Jpn J Cancer Res 64: 59
Maehara Y, Kusumoto T, Sakaguchi Y, Kusumoto H, Kido Y, Anai H, Sugimachi K (1989) Pyrimidine nucleotide synthesis is more extensive in poorly differentiated than in well-differentiated human gastric carcinoma. Cancer 63: 96
Maehara Y, Kusumoto T, Kusumoto H, Anai H, Sakaguchi Y, Kido Y, Okamura T, Korenaga D, Sugimachi K (1989) 5-fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase. Cancer 63: 1693
Maehara Y, Moriguchi S, Sakaguchi Y, Emi Y, Kohnoe S, Tsujitani S, Sugimachi K (1990) Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 45: 169
Maehara Y, Emi Y, Moriguchi S, Takahashi I, Yoshida M, Kusumoto H, Sugimachi K (1992) Postoperative chemotherapy for patients with advanced gastric cancer. Am J Surg 163: 577
Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M (1992) Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer 65: 413
Nakajima T, Inokuchi K, Hattori T, Inoue K, Taguchi T, Kondou T, Abe O, Kikuchi K, Tanabe T, Ogawa N (1989) Multi-institutional cooperative study of adjuvant immunochemotherapy for gastric cancer — five-year survival rate (in Japanese, with English abstract). Jpn J Cancer Chemother 16: 799
Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng C-C, Imai S, Tobe T (1991) In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 32: 335
Schabel FM (1975) Concepts for systemic treatment of micrometastases. Cancer 35: 15
Toge T, Yamaguchi Y, Kegoya Y, Baba N, Yanagawa E, Hattori T (1989) Blocking of lymphocyte surface binding sites for the soluble suppressor factor by protein-bound polysaccharide. PSK. Int J Immunopharmacol 11: 9
Torisu M, Katano M, Kimura Y, Itoh H, Takesue M (1983) New approach to management of malignant ascites with a streptococcal preparation. OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93: 357
Tsuijtani S, Furusawa T, Tamada R, Okamura T, Yasumoto K, Sugimachi K (1987) Langerhans cells and prognosis in patients with gastric carcinoma. Cancer 59: 501
Tsujitani S, Abe Y, Korenaga D, Saitoh A, Watanabe A, Sugimachi K (1990) Intraperitoneal administration of the biological response modifier OK-432 and peritoneal recurrence following gastrectomy. Hepatogastroenterology 37: 498
Tsujitani S, Kakeji Y, Orita H, Watanabe A, Kohnoe S, Baba H, Anai H, Maehara Y, Sugimachi K (1992) Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer Res 12: 645
Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita H (1984) Krestin (PSK) Cancer Treat Rev 11: 131
Uchida A, Hoshino T (1980) Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 45: 476
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maehara, Y., Inutsuka, S., Takeuchi, H. et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer Chemother. Pharmacol. 33, 171–175 (1993). https://doi.org/10.1007/BF00685337
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685337